Engineering CAR T Cells with Biomaterials.
Incorporating biomaterials into the design of CAR T cells may yield new, improved versions of this immunotherapy. Two preclinical studies indicate the potential of using biodegradable nanoparticles to program circulating T cells into CAR T cells in situ, and delivering these therapeutic cells directly to solid tumors via small dissolvable sponges.